Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults with Progressive Vitiligo

NCT ID: NCT04237103

Last Updated: 2024-11-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-05-23
• Study Completion Date: 2025-10-10

Brief Summary

This is a phase 2, randomized, double blind, multicenter study evaluating the efficacy and safety of the combination of methotrexate plus UVB TL01 in vitiligo.

Detailed Description

Treatment Strategy: Multicentric, parallel double blind randomized phase 2 prospective study comparing MTX taken orally once a week + narrowband UVB TL01 versus placebo + narrowband UVB TL01 Follow-up of the study: patients included in this study will start MTX 2 months before starting narrowband UVB TL01. Phototherapy will be performed twice a week during 6 months. Follow-up visit will be done at month 2, 4 and month 8. Phone calls to the patient will be done at month 6

Conditions

Vitiligo

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

methotrexate

Methotrexate once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months after Methotrexate therapy for 6 months.

Group Type: EXPERIMENTAL

Methotrexate

Intervention Type: DRUG

oral capsules taken once a week

placebo

Placebo once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months afterplacebo therapy, for 6 months.

Group Type: PLACEBO_COMPARATOR

Placebos

Intervention Type: DRUG

Administered identically to the experimental group

Interventions

Methotrexate

oral capsules taken once a week

Intervention Type: DRUG

Placebos

Administered identically to the experimental group

Intervention Type: DRUG

Other Intervention Names

narrow-band UVB phototherapy; narrow-band UVB phototherapy

Eligibility Criteria

Inclusion Criteria

• Subject male or female age over 18 years old
• Diagnosis of non-segmental (symmetrical) vitiligo with body surface area ≥10%
• Active non-segmental vitiligo defined by Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND Presence of hypochromic aspect under Wood's lamp examination and/or perifollicular hypopigmentation under Wood's lamp examination.
• Signed informed consent document
• Male patients agreeing to use a reliable method of birth control during the study i. e. preservative and for at least 6 months following the last dose of investigational product, the patient's partner treated by methotrexate must be notified of the teratogenic risk of methotrexate and should be under effective contraception throughout the study and for at least 6 months following the last dose of investigational product.
• Women of childbearing potential who are negatively tested for pregnancy and agree to use a reliable method of birth control (every month) or remain abstinent during the study and for at least 6 months following the last dose of investigational product. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring
• Patient registered to the French Social Security

Exclusion Criteria

• Segmental or mixed vitiligo
• Patients who have known active liver disease (with the exception of a simple liver steatosis, transaminases and/or alkaline phosphatases > 2 ULM ) or history of liver disease in the past 2 years, whatever the related diagnosis but which could interfere with MTX safety and according to the summary of the SmPC.
• Intake of restricted medications (cf section VIII.5.) or other drugs considered likely to interfere with the safe conduct of the study, as assessed by the investigator and according to the Summary of the Product Characteristics (SmPC), including any drug intakes that could interfere with methotrexate metabolism or that could enhance liver and /or hematologic toxicity and according to the SmPC
• Patient with evidence or positive test for HIV, Hepatitis C virus, Hepatitis B virus (patients who are negative for hepatitis B surface antigen but positive for anti-hepatitis B anti body (HBsAb+ and HBcAb+) and negative for serum HBV DNA may participate in the study
• High alcohol intake defined as more than 60 g of daily intake (approx daily intake of 0.5 l of wine or equivalent),
• Patients who have a known allergy or hypersensitivity to MTX
• Patients who have a known serious adverse event to MTX prior to the trial leading to MTX discontinuation in the past
• Presence of significant hematologic or renal disorder or abnormal laboratory values at screening that, in the opinion of the investigator is associated with an unacceptable risk to the patient to participate in the study
• Clinical laboratory test results at screening that are outside a normal reference rating for the population and are considered clinically significant, or/and have any of the following specific abnormalities:
• Total white blood cell count <3G/L
• Neutrophil count < 1.5 G/l
• Lymphocytes count < 0.5G/l
• Platelet count < 100 G/l
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)>3 times the upper limit of normal (ULM)
• Hemoglobin <8.5g/dL (85.0 g/L)
• Creatinine clearance <40ml/min (Cockcroft formula)
• For women: pregnant or breast feeding
• Patients who have an active or serious infection or history of infections (bacterial, viral, fungal or mycobacteria), requiring hospitalization or intra venous anti-infectives infusion within 4 weeks prior to the baseline,
• Patients who have primary or secondary active immunodeficiency
• Patients who had live vaccine administration within 4 weeks prior to baseline
• Patients who had already been treated by at least 250 sessions of phototherapy - Patients who have any current or active cancer (with the exception of patient with successfully treated with in situ cervix carcinoma)
• Patients who had history of malignancy within 5 years prior to the trial that could contraindicate the use of an immunosuppressant
• Patients who will not be available for protocol which require study visits or procedures
• Patients who is not affiliated to the French Social Security system
• Patients unable to give informed consent and/or comply with all required study procedures

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Bordeaux

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Julien SENESCHAL, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Bordeaux

Locations

Service de Dermatologie - Hôpital Saint-André

Bordeaux, Bordeaux, France

Site Status: RECRUITING

Centre Hospitalier de Pau

Pau, , France

Site Status: RECRUITING

Centre Hospitalier de Périgueux

Périgueux, , France

Site Status: RECRUITING

Service de Dermatologie - CHU de Toulouse - Hopital Purpan

Toulouse, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Julien SENESCHAL, MD, PhD

Role: CONTACT

julien.seneschal@chu-bordeaux.fr

+335 56 79 49 63

Sitraka RASOLOFO

Role: CONTACT

sitraka.rasolofo@chu-bordeaux.fr

+335.56.82.06.55

Facility Contacts

Julien SENESCHAL, MD

Role: primary

julien.seneschal@chu-bordeaux.fr

+33 (0)5 56 79 47 05

Alain TAIEB, Prof

Role: backup

Julien SENESCHAL, MD

Role: backup

Thomas JOUARY, MD

Role: primary

thomas.jouary@ch-pau.fr

+335 59 72 67 96

Thomas JOUARY, MD

Role: backup

Jérôme MARIE, MD

Role: primary

jerome.marie@ch-perigueux.fr

+335 53 45 26 43

Jérôme MARIE, MD

Role: backup

Juliette MAZEREEUW-HAUTIER, MD, PhD

Role: primary

mazereeuw-hatier.j@chu-toulouse.fr

+335 67 77 81 41

Carle PAUL, Pr.

Role: backup

Other Identifiers

CHUBX 2017/44

Identifier Type: -

Identifier Source: org_study_id